Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapa-LiT: Dapagliflozin vs Sitagliptin in Diabetes and Liver Transplantation
NCT05042505Completed
- Sponsor
- Medanta
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dapagliflozin in diabetes mellitus (DM) and hepatic steatosis (2 arms), sponsored by Medanta. Primary endpoint: Changes from baseline in liver and pancreatic fat content at 12 months. Started Jan 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus (DM)hepatic steatosis
Beyond the preview
Go deeper on NCT05042505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042505.